On March 25, Gelonghui | Guichuang Tongqiao-B (02190.HK) announced that the Tongqiao Kirin blood flow guidance device independently developed by the Group has been approved for listing by the China Drug Administration (“State Drug Administration”). As the first fully developed remote closed dense mesh stent made in China, the Tsuqiao Kirin blood flow guide device will not only bring new treatment options for intracranial aneurysm treatment; at the same time, it will further enrich the company's product portfolio matrix and enhance the company's influence in the field of neurovascular interventional treatment in China. As of the date of this announcement, the company has obtained approval from the State Drug Administration for a total of 41 products in China.
According to the disclosure, a blood flow guide device (FD) is a revolutionary product for treating intracranial aneurysms, and in recent years it has gradually become one of the important treatments for intracranial aneurysms, especially large or large aneurysms. The Tsuqiao Kirin blood flow guide device is the first fully developed remote closed mesh holder made in China. It uses nickel-titanium coated platinum material to achieve full body imaging, while the remote end uses a closed design. Compared with similar products on the market, the Tsuqiao Kirin blood flow guide device has better adhesion and visibility during surgery, and can improve the visibility and safety of intraoperative operation; at the same time, the product model is more complete, which can meet the treatment needs of different clinical lesions.